Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT
· Real-Time Price · USD
7.15
0.01 (0.14%)
At close: Sep 26, 2025, 11:07 AM
0.14% (1D)
| Bid | 7.13 |
| Market Cap | 221.66M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -59.38M |
| EPS (ttm) | -1.86 |
| PE Ratio (ttm) | -3.84 |
| Forward PE | -3.75 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 7.15 |
| Volume | 81,312 |
| Avg. Volume (20D) | 693,849 |
| Open | 7.11 |
| Previous Close | 7.14 |
| Day's Range | 6.97 - 7.19 |
| 52-Week Range | 1.73 - 11.41 |
| Beta | 3.38 |
| Ex-Dividend Date | n/a |
About SGMT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SGMT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SGMT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
+6.36%
Sagimet Biosciences shares are trading higher afte...
Unlock content with
Pro Subscription
3 months ago
+12.4%
Sagimet Biosciences shares are trading higher after the company announced its Phase 3 Denifanstat acne therapy clinical trial met all primary and secondary endpoints.
3 weeks ago · seekingalpha.com
Sagimet Gains Momentum As FDA Eases Path For MASH Drug DevelopmentSagimet Biosciences offers a unique play in MASH with Denifanstat, a FASN inhibitor showing both fat reduction and fibrosis regression in Phase 2b. The FDA's acceptance of non-invasive trial endpoints...
